Data Sheet 1_Clinical outcomes and their relationship with tigecycline exposure in critically ill patients with drug resistant infections.pdf

The exposure-clinical outcome relationship was analyzed, and multivariate logistic regressions were performed to identify risk factors that associated with outcome.</p>Results<p>A total of 130 patients were included. The most common infection type was low respiratory tract infection (76/130), and carbapenem-resistant Acinetobacter baumannii was the most common pathogen (64/130). The median tigecycline treatment length was 12 days.

The median AUC was 14.0 mg h/L. The overall response rate and 28-day mortality rate were 50.0% and 36.2%, respectively. A lower fibrinogen level was the most common AE (51/130). ALB, PLT and combined use of cefoperazone-sulbactam were independent factors associated with clinical response, but AUC was negatively associated with clinical response.</p>Conclusion<p>The clinical outcome of tigecycline in critically ill patients with resistant pathogen infection was satisfactory, but negative relationship between tigecycline exposure and outcome was found and the PK/PD profile in these patients should be revisited.</p>